Last reviewed · How we verify
NCT04659447
Clinical Study of Platelet-rich Plasma Promoting Tendon-bone Healing in Anterior Cruciate Ligament Reconstruction
Phase 1 trial testing Platelet-Rich Plasma in Sports Injury in 60 participants. Status unknown.
9 November 2021
Quick facts
| Lead sponsor | Beijing Tsinghua Chang Gung Hospital |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 1 July 2016 |
| Primary completion | 9 November 2021 |
| Estimated completion | 9 November 2021 |
Drugs / interventions tested
- Platelet-Rich Plasma
Conditions studied
- Sports Injury — all drugs for Sports Injury →
Sponsor
Beijing Tsinghua Chang Gung Hospital
Who can join
Adults 15 to 50, any sex, with Sports Injury. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Anterior cruciate ligament (ACL) injury is a common knee injury, which seriously affects the living ability and sport level of the injured. ACL reconstruction is the main method to treat ACL injury. Due to the reconstructive ligament needs a tendon bone healing and ligament maturation, therefore, in the ACL anatomical study, reconstruction surgery and reconstruction materials under the condition of constant progress, how to improve the ACL reconstruction of tendon bone healing and shorten the time of the ligament mature, improve the clinical effect of ACL reconstruction, has become the focus in the ACL reconstruction. Autologous platelet-rich plasma (PRP) is full of growth factors and bioactive factors, which has the function of promoting tissue healing, anti-inflammatory and analgesic effects. At the same time of anterior cruciate ligament reconstruction, using autologous PRP in the bone channel might promote tendon bone healing and ligament maturing after ACL reconstruction, promote the recovery of proprioception, prevent bone channel expanding, shorten the postoperative recovery time, speed up the patients recovery exercise ability, improve the clinical effect of ACL reconstruction. In this study, patients with ACL injuries were randomly divided into two groups: one group underwent ACL anatomical reconstruction, and the other group underwent ACL anatomical reconstruction with PRP. Various clinical scores, KT-2000, Biodex and imaging tests were used to evaluate the differences in the clinical effects of the two surgical methods in terms of postoperative pain, joint swelling, knee function, joint stability, muscle strength recovery, bone channel expanding, ligament vasinization, and ligament maturation.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Strategies for promoting tendon-bone healing: Current status and prospects.
Yang C, Teng Y, Geng B, Xiao H, et al · · 2023 · cited 35× · PMID 36777256 · DOI 10.3389/fbioe.2023.1118468 -
Clinical Use of Platelet-Rich Plasma to Promote Tendon-Bone Healing and Graft Maturation in Anterior Cruciate Ligament Reconstruction-A Randomized Controlled Study.
Gong H, Huang B, Zheng Z, Fu L, et al · · 2022 · cited 18× · PMID 35103026 · DOI 10.1007/s43465-021-00533-z -
Strategies to promote tendon-bone healing after anterior cruciate ligament reconstruction: Present and future.
Tian B, Zhang M, Kang X. · · 2023 · cited 16× · PMID 36994361 · DOI 10.3389/fbioe.2023.1104214 -
Platelet-Rich Plasma in Anterior Cruciate Ligament Reconstruction: An Updated Systematic Review and Meta-Analysis of Clinical and Radiological Outcomes.
Abdallah A, Assaf G, Chahine C, Orm GA, et al · · 2026 · PMID 41976826 · DOI 10.3390/jcm15072526
Verify or expand the search:
- PubMed search for NCT04659447
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Platelet-Rich Plasma
Trials testing the same drug.
- NCT07184307 — Platelet-Rich Plasma Versus Botulinum Toxin for Refractory Overactive Bladder: A Randomized Trial · NA · recruiting
- NCT06535425 — Participants With Knee Osteoarthrosis · NA · completed
- NCT04640662 — The Effects of Platelet-Rich Plasma Versus Prolotherapy On Rotator Cuff Tendinopathy: A Randomized Controlled Trial. · Phase 1 · completed
- NCT03674203 — Efficacy of Platelet-rich Plasma in Treatment of Melasma · Phase 2 · completed
- NCT03548662 — The Effect of Platelet Rich Plasma Injection Combined With Exercise Rehabilitation in Patients With Rotator Cuff Tear · Phase 1 · completed
Other recruiting trials for Sports Injury
Currently open trials in the same condition.
- NCT06739785 — Turkish Translation of SportsConcussion Assesment Tool 6 · active not recruiting
Other Beijing Tsinghua Chang Gung Hospital trials
Trials by the same sponsor.
- NCT07123675 — AI-Assisted Blood Pressure Control During Anesthesia · NA · not yet recruiting
- NCT07152496 — Host-Microbe Interactions in Biliary Dilatation · not yet recruiting
- NCT07330271 — PTC-Guided Therapy for Peritoneal Mesothelioma · NA · recruiting
- NCT07328737 — One vs Three HIPEC Cycles After CRS for Pseudomyxoma Peritonei · NA · recruiting
- NCT07044947 — Oteseconazole in the Treatment of Adults With Vulvovaginal Candidiasis(VVC) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04659447 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Tsinghua Chang Gung Hospital
- Last refreshed: 9 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04659447.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing